Ginkgo Bioworks $DNA released their 2023 results, and it's not pretty. Downstream revenues are drying up, and milestone pool opportunities aren't providing as many growth opportunities as investors had hoped. Cell engineering revenues disappointed with only $144 million in 2023 versus the expected $175 million - flat revenue growth year-over-year. Will Ginkgo be able to turn this ship around? Or is the synthetic biology company just another wonderful story?


Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/7-cb8SO-d6c.

Ver todos los episodios